Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma
- PMID: 18648664
- PMCID: PMC2464714
- DOI: 10.1371/journal.pone.0002779
Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma
Abstract
Aims: Deleted in liver cancer 1 (DLC1), a member of RhoGTPase activating protein (GAP) family, is known to have suppressive activities in tumorigenicity and cancer metastasis. However, the underlying molecular mechanisms of how DLC1 suppresses cell motility have not been fully elucidated. Rho-kinase (ROCK) is an immediate down-stream effector of RhoA in mediating cellular cytoskeletal events and cell motility. In the present study, we aimed to investigate the effects of DLC1 on Rho/ROCK signaling pathway in hepatocellular carcinoma (HCC).
Methodology/principal findings: We demonstrated that DLC1 negatively regulated ROCK-dependent actomyosin contractility. From immunofluorescence study, we found that ectopic expression of DLC1 abrogated Rho/ROCK-mediated cytoskeletal reorganization including formation of stress fibers and focal adhesions. It also downregulated cortical phosphorylation of myosin light chain 2 (MLC2). These inhibitory events by DLC1 were RhoGAP-dependent, as RhoGAP-deficient mutant of DLC1 (DLC1 K714E) abolished these inhibitory events. In addition, from western study, DLC1 inhibited ROCK-related myosin light chain phosphatase targeting unit 1 (MYPT1) phosphorylation at Threonine 853. By examining cell morphology under microscope, we found that ectopic expression of dominant-active ROCK released cells from DLC1-induced cytoskeletal collapse and cell shrinkage.
Conclusion: Our data suggest that DLC1 negatively regulates Rho/ROCK/MLC2. This implicates a ROCK-mediated pathway of DLC1 in suppressing metastasis of HCC cells and enriches our understanding in the molecular mechanisms involved in the progression of hepatocellular carcinoma.
Conflict of interest statement
Figures








Similar articles
-
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.Cancer Res. 2005 Oct 1;65(19):8861-8. doi: 10.1158/0008-5472.CAN-05-1318. Cancer Res. 2005. PMID: 16204057
-
DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.Oncogene. 2014 Feb 6;33(6):724-33. doi: 10.1038/onc.2013.7. Epub 2013 Feb 4. Oncogene. 2014. PMID: 23376848
-
Endosomes generate localized Rho-ROCK-MLC2-based contractile signals via Endo180 to promote adhesion disassembly.J Cell Biol. 2006 Oct 23;175(2):337-47. doi: 10.1083/jcb.200602125. Epub 2006 Oct 16. J Cell Biol. 2006. PMID: 17043135 Free PMC article.
-
Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.Int J Cancer. 2014 Jul 15;135(2):264-9. doi: 10.1002/ijc.28505. Epub 2013 Oct 17. Int J Cancer. 2014. PMID: 24114040 Review.
-
RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it.Liver Int. 2010 May;30(5):642-56. doi: 10.1111/j.1478-3231.2010.02232.x. Liver Int. 2010. PMID: 20726051 Review.
Cited by
-
DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.Leukemia. 2009 Feb;23(2):383-90. doi: 10.1038/leu.2008.285. Epub 2008 Oct 16. Leukemia. 2009. PMID: 18923442 Free PMC article.
-
Overexpression of engulfment and cell motility 1 promotes cell invasion and migration of hepatocellular carcinoma.Exp Ther Med. 2011 May;2(3):505-511. doi: 10.3892/etm.2011.229. Epub 2011 Mar 18. Exp Ther Med. 2011. PMID: 22977532 Free PMC article.
-
Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells.Sci Rep. 2017 Jan 11;7:40590. doi: 10.1038/srep40590. Sci Rep. 2017. PMID: 28074910 Free PMC article.
-
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.PLoS One. 2013 Jun 27;8(6):e68226. doi: 10.1371/journal.pone.0068226. Print 2013. PLoS One. 2013. PMID: 23826380 Free PMC article.
-
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.Front Pharmacol. 2022 Jan 3;12:775084. doi: 10.3389/fphar.2021.775084. eCollection 2021. Front Pharmacol. 2022. PMID: 35046810 Free PMC article. Review.
References
-
- Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998;58:2196–2199. - PubMed
-
- Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 2005;65:8861–8868. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous